1 |
Poter RN, Smith W, Craft IL. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet II 1984; 1284-5
|
2 |
Olivennes F, Fanchin R, Bouchard P, et al. The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix is an in vitro fertilization-embryo transfer programme. Fertil Steril 1994; 62: 468-76
DOI
PUBMED
|
3 |
Smitz J, Camus M, Devroey P. Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in vitro fertilization. Hum Reprod 1990; 5: 933-40
DOI
PUBMED
|
4 |
Graft I, Gorgy A, Jennifer H, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? 1999; 12(22): 2959-62
|
5 |
Demetrios M, Michael MA, Selwyn PO, Susan ML, Joseph FM, Spyros NP. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: Cycle performance and in vitro steroidogenesis of granulosa-lutein cells. American Journal of Obstetrics and Gynecology 1995; 172(5): 1518-25
DOI
ScienceOn
|
6 |
Hoff JD, Lasley BL, Yen SSC. The functional relationship between priming and releasing actions of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1979; 49: 8-15
DOI
|
7 |
Ben-Rafael Z, Strauss JF Ill, Mastroianni L Jr, Flickinger GL. Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation. Fertil Steril 1986; 46: 586-92
DOI
PUBMED
|
8 |
Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56:213-20
DOI
PUBMED
|
9 |
Urman B, Pride SM, Yuen BH. Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum Reprod 1992; 7: 918-22
DOI
|
10 |
Albano C, Platteau P, Devroey P. Gonadotropin releasing hormone antagonist: how good is the new hope? Curr Opin Obstet Gynecol 2001; 13: 257-62
|
11 |
Albrecht JL, Tomich PG. The maternal and neonatal outcome of triple gestations. American Journal of Obstetrics and Gynecology 1996; 174: 1551-6
DOI
ScienceOn
|
12 |
Elchalal U, Schenken JG. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Hum Reprod 1997; 12: 1129-37
DOI
ScienceOn
|
13 |
Andreyko JL, Marshall LA, Dumesic DA, Jaffe RB. Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet Gynecol Surv 1987; 42: 1-21
DOI
|
14 |
Judith AF Huirne, Cornelis B Lambalk. Gonadotropin-releasing-hormone-receptor antagonists. The Lancet 2001; 358: 1793-803
DOI
ScienceOn
|
15 |
Yen SSC, Jaffe RB. Reproduction. Endocrinology 3rd Ed, Philadelpia, WB Saunders 1991; 593-7
|
16 |
Gysler MG, March CM, Mishell DR, Gailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982;37: 161-7
DOI
|
17 |
Chung-hoon Kim, Hee-done C, Eun-hee K, Hyung-sik C, Byund-moon K, Yoon-seok C. The effects of somatostatin analogue on ovarian response to ovulation induction in patients with polycystic ovarian syndrome. 대한산부회지 1999; 42(3): 496-503
|
18 |
Albano C, Felberbaum R, Smitz J, et al. On behalf of the European Cetrorelix Study Group. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 3: 526-31
|
19 |
Tummon IS, Daniel SAJ, Kaplan BR, Nisker JA, Yuzpe AA. Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro fertilizatin. Fertil Steril 1992; 58:563-8
DOI
PUBMED
|
20 |
Falcone T, Bourque J, Granger L, Hemmings R, Miron P. Polycystic ovary syndrome. Current Roblems Obset Gynecol Fertil 1993; 16: 72-89
|
21 |
Yen SSC. The polycystic ovarian disease. Clin Endocrinol (Oxford) 1980; 12: 177-207
DOI
|
22 |
Albano C, Riethmuller-Winzen H, Smitz J, Van Steirteghem A, Camus M, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67;5:917-22
|
23 |
Hall JE. Gonadotropin-releasing hormone antagonists: Effects on the ovarian follicle and corpus luteum. Clin Obstet Gynecol 1993; 36:744-52
DOI
|
24 |
Borm G, Mannaerts B. The European Orgalutran Study Group. Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490-8
DOI
ScienceOn
|
25 |
Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987;48:57-61
PUBMED
|
26 |
Wu TCJ, Gelety TH, Jih MH, Fournet N, Buyalos RP. Successful management of predicted severe ovarian hyperstimulation syndrome with gonadotropin-releasing hormone agonist. J Assist Reprod Genet 1992; 622-4
|
27 |
Ulug U, Bahceci M, Erden H, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002; 17(2):310-3
DOI
ScienceOn
|
28 |
Egbase PE, Sharhan M, Grudzinskas J. 'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod 2002; 17: 1212-6
DOI
ScienceOn
|